Table 1 Baseline clinical and demographic characteristics of the trial sample

Male gender^a

23 (59.0)

Age (years)^b

54.00 ± 8.7

Body mass index (kg/m²)^b

28.67 ± 4.5

No cirrhosis

26 (66.7)

Cirrhosis

9 (23.1)

No cirrhosis

2 (5.1)

Cirrhosis

2 (5.1)

F1–2

21 (53.8)

F3–4

18 (46.2)

Telaprevir

21 (53.8)

Boceprevir

17 (43.6)

Simepravir

1 (2.6)

Haemoglobin (g/dL)^b

14.83 ± 1.0

Platelets (10³/μL)^b

180.18 ± 50.9

INR^c

1.00 (0.11)

ALT (IU/L)^c

56 (44)

AST (IU/L)^c

47 (37)

AP (IU/L)^c

74 (25)

GGT (IU/L)^c

61 (98)

Bilirubin (mg/dL)^b

0.66 ± 0.3

Albumin (g/dL)^b

4.27 ± 0.2

Creatinine (mg/dL)^b

0.76 ± 0.1